The Pharma Letter44m
New CEO to advance VectorY’s ALS therapy VTx-002
VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...
Can you get disability benefits for ALS? 3 things to do if your claim is denied
If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...
BioSpace7h
5 Clinical Assets That Flopped in 2024
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
Pharmaceutical Technology20h
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.